# The REFLECT Trial: Cerebral Protection to Reduce Cerebral Embolic Lesions After Transcatheter Aortic Valve Implantation

Study · id `cardio:ct-nct02536196` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02536196](<https://clinicaltrials.gov/study/NCT02536196>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02536196

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 478 participants.

## Technical summary

Registry record NCT02536196. Randomized; single masking; primary purpose prevention. Start 2016-06 (actual); primary completion 2019-05 (actual). Results posted on 2021-02-18.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Not applicable
- Enrolled: 478 participants (enrolled count; ClinicalTrials.gov record NCT02536196, source copy `cardio:ctgov-nct02536196-2021-02-18`, retrieved 2026-10-26)
- Started: 2016-06 (actual) (ClinicalTrials.gov record NCT02536196, source copy `cardio:ctgov-nct02536196-2021-02-18`, retrieved 2026-10-26)
- Primary completion: 2019-05 (actual) (ClinicalTrials.gov record NCT02536196, source copy `cardio:ctgov-nct02536196-2021-02-18`, retrieved 2026-10-26)
- Completion: 2019-06 (actual) (ClinicalTrials.gov record NCT02536196, source copy `cardio:ctgov-nct02536196-2021-02-18`, retrieved 2026-10-26)
- Results first posted: 2021-02-18 (ClinicalTrials.gov record NCT02536196, source copy `cardio:ctgov-nct02536196-2021-02-18`, retrieved 2026-10-26)
- Countries: United States; Germany; Italy; Netherlands (ClinicalTrials.gov record NCT02536196, source copy `cardio:ctgov-nct02536196-2021-02-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02536196-2021-02-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: The REFLECT Trial: Cerebral Protection to Reduce Cerebral Embolic Lesions After Transcatheter Aortic Valve Implantation
- Condition: Symptomatic Aortic Stenosis
- Intervention (Device): Embolic Protection Device
- Intervention (Procedure): Transcatheter aortic valve implantation (TAVI)
- Lead sponsor: Keystone Heart
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)

## Provenance

Content hash: de66af9d565520b0fb32b415df9a24c942e0c4b6b4f96b97b2689c02caad8166
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
